PMID- 36615606
OWN - NLM
STAT- MEDLINE
DCOM- 20230110
LR  - 20230111
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 28
IP  - 1
DP  - 2023 Jan 3
TI  - Targeted Delivery of Sunitinib by MUC-1 Aptamer-Capped Magnetic Mesoporous Silica 
      Nanoparticles.
LID - 10.3390/molecules28010411 [doi]
LID - 411
AB  - Magnetic mesoporous silica nanoparticles (MMSNPs) are being widely investigated 
      as multifunctional novel drug delivery systems (DDSs) and play an important role 
      in targeted therapy. Here, magnetic cores were synthesized using the thermal 
      decomposition method. Further, to improve the biocompatibility and 
      pharmacokinetic behavior, mesoporous silica was synthesized using the sol-gel 
      process to coat the magnetic cores. Subsequently, sunitinib (SUN) was loaded into 
      the MMSNPs, and the particles were armed with amine-modified mucin 1 (MUC-1) 
      aptamers. The MMSNPs were characterized using FT-IR, TEM, SEM, electrophoresis 
      gel, DLS, and EDX. MTT assay, flow cytometry analysis, ROS assessment, and 
      mitochondrial membrane potential analysis evaluated the nanoparticles' biological 
      impacts. The physicochemical analysis revealed that the engineered MMSNPs have a 
      smooth surface and spherical shape with an average size of 97.6 nm. The 
      biological in vitro analysis confirmed the highest impacts of the targeted MMSNPs 
      in MUC-1 overexpressing cells (OVCAR-3) compared to the MUC-1 negative MDA-MB-231 
      cells. In conclusion, the synthesized MMSNP-SUN-MUC-1 nanosystem serves as a 
      unique multifunctional targeted delivery system to combat the MUC-1 
      overexpressing ovarian cancer cells.
FAU - Torabi, Mitra
AU  - Torabi M
AUID- ORCID: 0000-0002-9012-4976
AD  - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz 
      University of Medical Sciences, Tabriz 51656-65811, Iran.
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical 
      Sciences, Tabriz 516664-14766, Iran.
FAU - Aghanejad, Ayuob
AU  - Aghanejad A
AUID- ORCID: 0000-0001-5636-4143
AD  - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz 
      University of Medical Sciences, Tabriz 51656-65811, Iran.
FAU - Savadi, Pouria
AU  - Savadi P
AUID- ORCID: 0000-0001-9387-082X
AD  - Department of Environmental, Biological and Pharmaceutical Sciences and 
      Technologies (Di.S.T.A.Bi.F.), University of Campania "Luigi Vanvitelli", Via 
      Vivaldi 43, 81100 Caserta, Italy.
FAU - Barzegari, Abolfazl
AU  - Barzegari A
AD  - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz 
      University of Medical Sciences, Tabriz 51656-65811, Iran.
FAU - Omidi, Yadollah
AU  - Omidi Y
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern 
      University, Fort Lauderdale, FL 33328, USA.
FAU - Barar, Jaleh
AU  - Barar J
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical 
      Sciences, Tabriz 516664-14766, Iran.
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern 
      University, Fort Lauderdale, FL 33328, USA.
LA  - eng
GR  - 971446/National Institute for Medical Research Development, Iran/
PT  - Journal Article
DEP - 20230103
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - V99T50803M (Sunitinib)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - 0 (Mucin-1)
SB  - IM
MH  - Humans
MH  - Female
MH  - Sunitinib
MH  - Cell Line, Tumor
MH  - Apoptosis
MH  - Silicon Dioxide/chemistry
MH  - Mucin-1/genetics
MH  - Spectroscopy, Fourier Transform Infrared
MH  - *Ovarian Neoplasms
MH  - *Nanoparticles/chemistry
MH  - Drug Delivery Systems/methods
MH  - Magnetic Phenomena
MH  - Porosity
PMC - PMC9824472
OTO - NOTNLM
OT  - anti-mucin 1 aptamer
OT  - magnetic mesoporous silica nanoparticles
OT  - ovarian cancer
OT  - sunitinib
OT  - targeted drug delivery
COIS- The authors report no conflict of interest.
EDAT- 2023/01/09 06:00
MHDA- 2023/01/11 06:00
PMCR- 2023/01/03
CRDT- 2023/01/08 01:35
PHST- 2022/11/24 00:00 [received]
PHST- 2022/12/22 00:00 [revised]
PHST- 2022/12/29 00:00 [accepted]
PHST- 2023/01/08 01:35 [entrez]
PHST- 2023/01/09 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2023/01/03 00:00 [pmc-release]
AID - molecules28010411 [pii]
AID - molecules-28-00411 [pii]
AID - 10.3390/molecules28010411 [doi]
PST - epublish
SO  - Molecules. 2023 Jan 3;28(1):411. doi: 10.3390/molecules28010411.